Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Long-Term Investments (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Long-Term Investments for 3 consecutive years, with $646000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Long-Term Investments fell 74.52% year-over-year to $646000.0, compared with a TTM value of $646000.0 through Sep 2024, down 74.52%, and an annual FY2023 reading of $110.2 million, up 3981.04% over the prior year.
  • Long-Term Investments was $646000.0 for Q3 2024 at Oramed Pharmaceuticals, down from $2.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $110.2 million in Q4 2023 and bottomed at $2000.0 in Q3 2022.
  • Average Long-Term Investments over 3 years is $13.9 million, with a median of $2.5 million recorded in 2023.
  • Peak annual rise in Long-Term Investments hit 126650.0% in 2023, while the deepest fall reached 89.26% in 2023.
  • Year by year, Long-Term Investments stood at $2.7 million in 2022, then surged by 3981.04% to $110.2 million in 2023, then tumbled by 99.41% to $646000.0 in 2024.
  • Business Quant data shows Long-Term Investments for ORMP at $646000.0 in Q3 2024, $2.3 million in Q2 2024, and $2.0 million in Q1 2024.